Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 10 of about 15   

Articles published

DVAX 15.34 -0.18 (-1.16%)
price chart
Analysts At William Blair Maintain Outperform On Dynavax Technologies
The firm points out that Dynavax has received the briefing book from the FDA by now and no news so far is good news. Moreover, Dynavax had communicated that if there were material information, the company would disclose it to the public. The firm ...
Related articles »  
Dynavax Shares Jump On Release Of FDA Briefing Materials
As I wrote earlier, Dynavax Technologies Corporation (NASDAQ:DVAX) announced on April 28, 2012, it had submitted a U.S. Biologics License Application, or BLA, to the FDA for HEPLISAV, its treatment for hepatitis B. The company is pursuing an indication ...
Dynavax's Heplisav Vaccine Works on Hepatitis B, FDA Says  Bloomberg
Related articles »  
Dynavax Gets Crushed After Advisory Committee Vote
Assuming that the FDA decision turns out to be no (a favorable bet), we can still infer that Dynavax will conduct additional safety studies that can be included in Heplislav's next BLA.
Dynavax Falls After Vaccine Fails to Win Panel Backing  Bloomberg
Dynavax plunges as panel questions Heplisav safety  Businessweek
Related articles »  
Despite Safety Concerns, Dynavax's Heplisav Should Receive FDA Approval
Dynavax is a clinical-stage biopharmaceutical company developing preventative and curative treatments for infectious and inflammatory diseases.
Related articles »  
Dynavax Upcoming Binary Event: HBV Vaccine Under Review By FDA Advisory ...
Dynavax Technologies Corporation (NASDAQ:DVAX) is a small biotech company with an upcoming binary event on its stock. The FDA advisory committee will meet on November 15, 201,2 to discuss the company's HBV vaccine.
Why Dynavax's HEPLISAV Is Likely To Be Approved: Impact On Future Vaccine ...
Dynavax's (NASDAQ:DVAX) HEPLISAV had an FDA Advisory Committee on November 15, 2012. The Advisory Committee voted 13 to one that HEPLISAV data adequately demonstrated immunogenicity.
Pre-Market Movers (Green Mountain, Knight Capital, Costco, Freeport-McMoRan ...
Groupon Inc. (GRPN) stock gained 2.53 percent to $4.06 in pre-market trading. The stock has a 52-week low of $2.60, a 52-week high of $25.84 and $2.60 billion in market capitalization.
Pre-Market Movers (Nokia, Pluristem, New Oriental, SAP, Dynavax, LG Display ...
Nokia Corp, Pluristem Therapeutics, New Oriental Education, SAP AG, Dynavax Technologies, LG Display Co, Sanofi SA and BHP Billiton are among the companies whose shares are moving in pre-market trading Wednesday.
Pre-Market Movers (Nokia, eBay, Deutsche Bank, Carnival, Facebook, Rio Tinto ...
Nokia Corp, eBay Inc, Deutsche Bank, Carnival Plc, Facebook, Rio Tinto, Dynavax Technologies and Frontline Ltd.
Can Dynavax overcome Heplisav blow?
Two weeks ago, an FDA panel dealt a blow to Dynavax Technologies ($DVAX), raising concerns about the safety of the company's hepatitis B vaccine, Heplisav. Shares dropped and investors tend to turn their backs on a company when stock prices go down.